Biotech

All Articles

Ascendis' dwarfism medication smash hits in phase 3, endangers BioMarin

.Ascendis Pharma has actually become a possible hazard to BioMarin's Voxzogo, stating phase 3 growth...

Despite ph. 3 overlook, Alkeus observes pathway in advance for eye ailment asset

.Though Alkeus Pharmaceuticals' oral eye disease property neglected to substantially decrease geogra...

Kairos goes social along with $6M IPO to cash trials of cancer medicine

.Along with a triad of biotechs hitting the Nasdaq on Friday, it was actually very easy to miss out ...

Vaccine and also Keytruda combination reliable in squamous cell cancer

.Immune checkpoint preventions are actually the superheroes of cancer cells treatment. Medications l...

Cue Biopharma mark time J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of notable management hirings, shootings and ...

Regeneron's Opdualag opponent reveals 57% action rate

.Regeneron is actually back along with long-term consequence for its own LAG-3 prevention and PD-1 p...

AstraZeneca posts data on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early consider the functionality of its internal antibody-dr...

iTeos- GSK's TIGIT superstar presents significant improvement

.After introducing a stage 3 launch based upon beneficial midstage results, iTeos and GSK are actual...

More joint FDA can accelerate uncommon condition R&ampD: record

.The FDA ought to be more available and collective to discharge a surge in commendations of unusual ...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It is actually an extraordinarily busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and...